ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 2 filers reported holding ARRAY BIOPHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,018,000 | +1070.1% | 21,968 | +515.9% | 0.00% | – |
| Q1 2019 | $87,000 | +4.8% | 3,567 | -39.3% | 0.00% | – |
| Q4 2018 | $83,000 | +38.3% | 5,879 | +47.3% | 0.00% | – |
| Q3 2018 | $60,000 | -10.4% | 3,991 | -1.3% | 0.00% | – |
| Q2 2018 | $67,000 | +63.4% | 4,043 | +61.2% | 0.00% | – |
| Q1 2018 | $41,000 | +28.1% | 2,508 | 0.0% | 0.00% | – |
| Q4 2017 | $32,000 | +68.4% | 2,508 | +66.3% | 0.00% | – |
| Q3 2017 | $19,000 | -98.6% | 1,508 | -99.1% | 0.00% | -100.0% |
| Q2 2017 | $1,376,000 | +10484.6% | 164,408 | +10802.4% | 0.00% | – |
| Q1 2017 | $13,000 | +8.3% | 1,508 | 0.0% | 0.00% | – |
| Q4 2016 | $12,000 | +300.0% | 1,508 | +281.8% | 0.00% | – |
| Q3 2016 | $3,000 | +200.0% | 395 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | -50.0% | 395 | -50.0% | 0.00% | – |
| Q1 2016 | $2,000 | -33.3% | 790 | 0.0% | 0.00% | – |
| Q4 2015 | $3,000 | -78.6% | 790 | -74.6% | 0.00% | – |
| Q2 2014 | $14,000 | – | 3,110 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 15,978,580 | $268,121,000 | 9.11% |
| BVF INC/IL | 4,672,195 | $78,399,000 | 7.65% |
| First Light Asset Management, LLC | 2,391,575 | $40,131,000 | 6.25% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 694,500 | $11,647,000 | 4.47% |
| Copernicus Capital Management, LLC | 286,797 | $4,812,000 | 3.49% |
| PACIFIC VIEW ASSET MANAGEMENT, LLC | 225,511 | $3,784,000 | 3.00% |
| SECTORAL ASSET MANAGEMENT INC | 1,566,477 | $26,285,000 | 2.94% |
| X-Square Capital, LLC | 173,802 | $2,917,000 | 2.18% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,618,654 | $43,941,000 | 1.48% |
| Birchview Capital, LP | 128,000 | $2,148,000 | 1.46% |